21
total announcements
ALIVUS.NS · 15 min delayed
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of investor/analyst meetings to be conducted from August 28, 2026, to September 2, 2026, in virtual and in-person formats.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the acquisition of 76% stake in IQGEN-X Pharma Private Limited for approximately INR 9.12 crores, subject to customary adjustments.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of investor/analyst meetings to be conducted on August 18-19, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has submitted its Business Responsibility & Sustainability Report for FY 2025-26, as per SEBI regulations.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting (AGM) to be held on September 8, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a scheduled investor/analyst meeting on August 12, 2026, to be attended by the company's representatives, including SBI Mutual Fund.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a scheduled investor/analyst meeting on August 12, 2026, in Mumbai, which may be subject to change.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about Transcript of earnings call held on July 31, 2026. The company reported revenues of INR640 crores, a 6.4% year-on-year growth during the quarter, driven by strong growth of 26.5% year-on-year in non-GPL business.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a copy of newspaper publication regarding intimation of 15th AGM.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the record date for the purpose of dividend as September 1, 2026, and the 15th Annual General Meeting will be held on September 8, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 2026. The company has recommended a final dividend of Rs.5.00 per Equity share of Rs.2 each for the financial year ended March 31, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has uploaded the audio recording of its Q1 FY2027 Earnings Call on its website, as per Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding the allotment of 32,000 Equity shares under the 'Employee Stock Option Scheme, 2021'. The paid-up share capital of the Company has increased to Rs. 24,55,42,896/-.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has reported Q1 FY27 results, with revenue growth of 6.4% YoY, driven by strong momentum in the non-GPL business, and EBITDA margins of 36.6%. The company expects revenue growth of 10-12% in FY27 and sustaining EBITDA margins in the 30-32% range.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced its financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 6,404 Mn, a growth of 6.4% YoY, driven by robust performance in the non-GPL business. EBITDA for Q1FY27 stood at Rs. 2,341 Mn, a growth of 29.1% YoY with margins at 36.6%, and PAT for Q1FY27 stood at Rs. 1,601 Mn, a growth of 31.8% YoY with margins at 25.0%. The company generated a strong free cash flow of Rs. 901 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 8,802 Mn as of June 30, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at Rs. 6,404.14 million, a 6% decrease from the previous quarter, and net profit for the period at Rs. 1,600.76 million.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has scheduled an earnings call for Q1 FY2026-27 on July 31, 2026, to discuss its financial performance.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of its Board Meeting on July 30, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.